Building and investing in longevity biotech ("LongBio") companies that address the molecular mechanisms of aging ("geroscience"). Bio: Sebastian A. Brunemeier is a biotech VC and company builder focused on longevity & regenerative medicine. He is Co-Founder and General Partner of Healthspan Capital, and CEO and Founder of ImmuneAGE Bio (stealth), focused on immune system rejuvenation. Over the last 5 years, he has co-founded 4 longevity biotech (“LongBio”) companies with a total equity value of >$600M. He was Co-Founder and Chief Investment Officer at Cambrian Biopharma, Founder and COO of Samsara Therapeutics, and Principal at Apollo Health Ventures (the first and largest aging-focused venture capital fund in the world with $200M AUM). Altogether, these organizations have raised ±$400M in the last 4 years. He was a Fulbright Fellow on the biology of aging, a Skaggs-Oxford Scholar at the Scripps Research Institute, and a SENS Foundation Scholar at the Buck Institute for Research on Aging. His education includes dropping out of the DPhil (PhD) program in biochemistry of aging at the University of Oxford as a Clarendon Scholar (to launch a biotech startup called Cambrian), a Master’s in Life Science Business Management and Molecular Neuroscience from the University of Amsterdam as an Amsterdam Excellence Scholar. He served as trustee of the British Society for Research on Aging, a mentor at The New York Academy of Sciences, and as an advisor or board member to: VitaDAO/Molecule.to, Equator Therapeutics, Revivo Therapeutics, and McKinsey & Company.A few of my presentations: https://www.youtube.com/playlist?list=PL1fK3UMPdqMvp_YbqK2fnPkTQBOYD2ww4